Annals of Hematology

, Volume 86, Issue 4, pp 277–282 | Cite as

Autologous peripheral blood stem cell transplantation in multiple myeloma using oral versus I.V. melphalan

  • J. Vela-Ojeda
  • M. A. García-Ruiz-Esparza
  • Y. Padilla-González
  • D. Gómez-Almaguer
  • C. H. Gutiérrez-Aguirre
  • D. Gómez-Rangel
  • A. Morales-Toquero
  • G. J. Ruiz-Delgado
  • J. L. Delgado-Lamas
  • G. J. Ruiz-Argüelles
Original Article

Abstract

Autologous peripheral blood stem cell transplantation is the therapy of choice for the treatment of multiple myeloma (MM) patients younger than 70 years old. Between August 1993 and November 2004, 54 patients with MM were autografted after conditioning with high-dose oral melphalan 140 mg/m2 in combination with etoposide and carmustine (28 patients) or with high-dose melphalan 200 mg/m2 I.V. (26 patients). The oral and IV melphalan groups were comparable. There were no significant differences in disease-free survival (DFS) and overall survival (OS) between the groups; however, in patients transplanted in remission, OS and DFS were better in the I.V. melphalan group. Four good-prognostic factors were identified: interval between diagnosis and transplant <18 months, number of prior chemotherapy lines ≤2, remission status (complete or partial), and the use of I.V. melphalan. In conclusion, I.V. melphalan is the therapy of choice for conditioning patients with MM who are in remission.

Keywords

Stem cell autotransplants Multiple myeloma Oral and I.V. melphalan 

Notes

Acknowledgements

This study was approved by the ethical committees of the participant hospitals and is in accordance with the Helsinki Declaration of 1975 and complies with the current health and research laws of México.

References

  1. 1.
    Ager S, Mahendra P, Richards EM, Bass G, Baglin TP, Marcus RE (1996) High-dose carmustine, etoposide and melphalan (BEM) with autologous stem cell transplantation: a dose-toxicity study. Bone Marrow Transplant 17:335–340PubMedGoogle Scholar
  2. 2.
    Alegre A, Lamana M, Arranz R, Fernandez-Villalta MJ, Tomas JF, Figuera A et al (1995) Busulfan and melphalan as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma. Br J Haematol 91:380–386PubMedGoogle Scholar
  3. 3.
    Attal M, Harousseau JL, Stoppa AM (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 335:91–97PubMedCrossRefGoogle Scholar
  4. 4.
    Barlogie B, Jagannath S, Naucke S, Mattox S, Bracy D, Crowley J et al (1998) Long-term follow-up after high-dose therapy for high-risk multiple myeloma. Bone Marrow Transplant 21:1101–1107PubMedCrossRefGoogle Scholar
  5. 5.
    Bergsagel DE (1989) Melphalan/prednisone vs drug combinations for plasma cell myeloma. Eur J Haematol 43(Suppl 51):117–123Google Scholar
  6. 6.
    Boccadoro M, Marmont F, Tribalto M (1991) VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone in the treatment of multiple myeloma even in high risk patients. J Clin Oncol 9:444–448PubMedGoogle Scholar
  7. 7.
    Bosanquet AG, Gilby ED (1982) Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma. Eur J Cancer Clin Oncol 18:355–362PubMedCrossRefGoogle Scholar
  8. 8.
    Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348:1875–1883PubMedCrossRefGoogle Scholar
  9. 9.
    Fassas A, Shaughnessy J, Barlogie B (2005) Cure of myeloma: hype or reality? Bone Marrow Transplant 35:215–224PubMedCrossRefGoogle Scholar
  10. 10.
    Gibson J, Ho PJ, Joshua D (2004) Evolving transplant options for multiple myeloma: autologous and nonmyeloablative allogeneic transplantation. Transplant Proc 8:2501–2503CrossRefGoogle Scholar
  11. 11.
    Vela-Ojeda J, Sanchez-Cortes E, Ayala-Sanchez M, Garcia-Chavez J, García-Ruiz Esparza MA, Tripp-Villanueva F et al (1998) Treatment of relapse and refractory multiple myeloma (MM) with intermediate doses of oral melphalan, dexamethasone and GM-CSF (M-80) versus VAD chemotherapy. Blood 92(10) Suppl 1, 284b, abstract # 4225Google Scholar
  12. 12.
    Kessinger A, Armitage JO, Landmark JD, Smith DM, Weisenburger DD (1988) Autologous peripheral hematopoietic stem cell transplantation restores hemopoietic function following marrow ablative therapy. Blood 71:723–727PubMedGoogle Scholar
  13. 13.
    Lahuerta JJ, Grande C, Blade J (2002) Myeloablative treatments for multiple myeloma: update of comparative study of different regimens used in patients from the Spanish Registry for Transplantation in Multiple Myeloma. Leuk Lymph 43:67–74CrossRefGoogle Scholar
  14. 14.
    Moreau P, Facon T, Attal M (2002) Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma. Final analysis of the IFM 95-02 randomized trial. Blood 99:731–735PubMedCrossRefGoogle Scholar
  15. 15.
    Reece PA, Kostasek D, Morris RG (1986) The effect of food on oral melphalan absorption. Cancer Chemother Pharmacol 49:1318–1321Google Scholar
  16. 16.
    Ruiz-Argüelles A (1992) Flow cytometry in the clinical laboratory. Principles, applications and problems. Ann Biol Clin 50:735–743Google Scholar
  17. 17.
    Ruiz-Argüelles GJ, Gómez-Rangel D, Ruiz-Delgado GJ, Aguilar-Romero L (2004) Multiple myeloma in México: a single institution, twenty-year experience. Arch Med Res 35:163–167PubMedCrossRefGoogle Scholar
  18. 18.
    Samuels BL, Bitran JD (1995) High-dose intravenous melphalan: a review. J Clin Oncol 13:1786–1799PubMedGoogle Scholar
  19. 19.
    Sarosy G, Leyland-Jones B, Soochan P, Cheson BD (1988) The systemic administration of intravenous melphalan. J Clin Oncol 6:1768–1782PubMedGoogle Scholar
  20. 20.
    Tricot G, Alberts DS, Johnson C (1996) Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. Clin Cancer Res 2:947–952PubMedGoogle Scholar
  21. 21.
    Vela-Ojeda J, García-Ruiz Esparza MA, Rosas-Cabral A, Padilla-González Y, García-Chavez J, Tripp-Villanueva F et al (2002) Intermediate doses of melphalan and dexamethasone are better than VAD chemotherapy for the treatment of primary plasma cell leukemia. Ann Hematol 81:262–267Google Scholar
  22. 22.
    Wildiers H, Highley S, De Bruijn EA, Van Oosterom AT (2003) Pharmacology of anticancer drugs in the elderly population. Clin Pharmacokinet 42:1213–1242PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • J. Vela-Ojeda
    • 1
  • M. A. García-Ruiz-Esparza
    • 1
  • Y. Padilla-González
    • 1
  • D. Gómez-Almaguer
    • 2
  • C. H. Gutiérrez-Aguirre
    • 2
  • D. Gómez-Rangel
    • 3
  • A. Morales-Toquero
    • 3
  • G. J. Ruiz-Delgado
    • 2
  • J. L. Delgado-Lamas
    • 4
  • G. J. Ruiz-Argüelles
    • 3
  1. 1.UMAE Hospital de Especialidades Centro Médico La Raza, IMSSMéxicoMéxico
  2. 2.Hospital Universitario de Nuevo LeónMonterrey Nuevo LeónMéxico
  3. 3.Centro de Hematología y Medicina Interna de PueblaPueblaMéxico
  4. 4.UMAE Hospital de Especialidades Centro Médico de Occidente, IMSSGuadalajara JaliscoMéxico

Personalised recommendations